Aprotinin reduces operative closure time and blood product use after pediatric bypass

John M. Costello, Carl L. Backer, Alberto De Hoyos, Helen J. Binns, Constantine Mavroudis

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: The use of aprotinin in children undergoing cardiopulmonary bypass is controversial. We hypothesized that aprotinin would reduce blood product use and operative closure time in selected pediatric patients. Methods: For a 6-month period starting in October 1999, consecutive cardiopulmonary bypass patients 6 months of age or less (n = 18) or having a repeat sternotomy (n = 18) received aprotinin. Similar consecutive patients from the preceding 6 months served as controls (n = 35 and 41, respectively). Data extracted from medical records included preoperative clinical characteristics, operative and postoperative procedures, and total blood product use. Results: Patients in the aprotinin and control groups were well matched with regard to preoperative and intraoperative variables. Patients 6 months of age or less who received aprotinin required less operative closure time when compared with controls (median, 93 vs 127 minutes, p = 0.004), and trended toward requiring fewer red blood cell unit exposures (median, three vs five exposures, p = 0.07). Patients undergoing repeat sternotomy who received aprotinin required less operative closure time when compared with controls (mean, 126 vs 159 minutes, p = 0.007), fewer red blood cell unit exposures (median three vs four exposures, p = 0.002), and fewer fresh-frozen plasma unit exposures (median, zero vs one exposure, p = 0.007). Conclusions: Aprotinin reduced operative closure time and blood product exposure in pediatric patients undergoing cardiopulmonary bypass who were 6 months of age or less or underwent a repeat sternotomy.

Original languageEnglish (US)
Pages (from-to)1261-1266
Number of pages6
JournalAnnals of Thoracic Surgery
Volume75
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

Aprotinin
Operative Time
Pediatrics
Sternotomy
Cardiopulmonary Bypass
Erythrocytes
Postoperative Care
Operative Surgical Procedures
Medical Records
Control Groups

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Aprotinin reduces operative closure time and blood product use after pediatric bypass. / Costello, John M.; Backer, Carl L.; De Hoyos, Alberto; Binns, Helen J.; Mavroudis, Constantine.

In: Annals of Thoracic Surgery, Vol. 75, No. 4, 01.04.2003, p. 1261-1266.

Research output: Contribution to journalArticle

Costello, John M. ; Backer, Carl L. ; De Hoyos, Alberto ; Binns, Helen J. ; Mavroudis, Constantine. / Aprotinin reduces operative closure time and blood product use after pediatric bypass. In: Annals of Thoracic Surgery. 2003 ; Vol. 75, No. 4. pp. 1261-1266.
@article{44ebf6b678b64c8d8e95853da976ef56,
title = "Aprotinin reduces operative closure time and blood product use after pediatric bypass",
abstract = "Background: The use of aprotinin in children undergoing cardiopulmonary bypass is controversial. We hypothesized that aprotinin would reduce blood product use and operative closure time in selected pediatric patients. Methods: For a 6-month period starting in October 1999, consecutive cardiopulmonary bypass patients 6 months of age or less (n = 18) or having a repeat sternotomy (n = 18) received aprotinin. Similar consecutive patients from the preceding 6 months served as controls (n = 35 and 41, respectively). Data extracted from medical records included preoperative clinical characteristics, operative and postoperative procedures, and total blood product use. Results: Patients in the aprotinin and control groups were well matched with regard to preoperative and intraoperative variables. Patients 6 months of age or less who received aprotinin required less operative closure time when compared with controls (median, 93 vs 127 minutes, p = 0.004), and trended toward requiring fewer red blood cell unit exposures (median, three vs five exposures, p = 0.07). Patients undergoing repeat sternotomy who received aprotinin required less operative closure time when compared with controls (mean, 126 vs 159 minutes, p = 0.007), fewer red blood cell unit exposures (median three vs four exposures, p = 0.002), and fewer fresh-frozen plasma unit exposures (median, zero vs one exposure, p = 0.007). Conclusions: Aprotinin reduced operative closure time and blood product exposure in pediatric patients undergoing cardiopulmonary bypass who were 6 months of age or less or underwent a repeat sternotomy.",
author = "Costello, {John M.} and Backer, {Carl L.} and {De Hoyos}, Alberto and Binns, {Helen J.} and Constantine Mavroudis",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0003-4975(02)04667-2",
language = "English (US)",
volume = "75",
pages = "1261--1266",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Aprotinin reduces operative closure time and blood product use after pediatric bypass

AU - Costello, John M.

AU - Backer, Carl L.

AU - De Hoyos, Alberto

AU - Binns, Helen J.

AU - Mavroudis, Constantine

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Background: The use of aprotinin in children undergoing cardiopulmonary bypass is controversial. We hypothesized that aprotinin would reduce blood product use and operative closure time in selected pediatric patients. Methods: For a 6-month period starting in October 1999, consecutive cardiopulmonary bypass patients 6 months of age or less (n = 18) or having a repeat sternotomy (n = 18) received aprotinin. Similar consecutive patients from the preceding 6 months served as controls (n = 35 and 41, respectively). Data extracted from medical records included preoperative clinical characteristics, operative and postoperative procedures, and total blood product use. Results: Patients in the aprotinin and control groups were well matched with regard to preoperative and intraoperative variables. Patients 6 months of age or less who received aprotinin required less operative closure time when compared with controls (median, 93 vs 127 minutes, p = 0.004), and trended toward requiring fewer red blood cell unit exposures (median, three vs five exposures, p = 0.07). Patients undergoing repeat sternotomy who received aprotinin required less operative closure time when compared with controls (mean, 126 vs 159 minutes, p = 0.007), fewer red blood cell unit exposures (median three vs four exposures, p = 0.002), and fewer fresh-frozen plasma unit exposures (median, zero vs one exposure, p = 0.007). Conclusions: Aprotinin reduced operative closure time and blood product exposure in pediatric patients undergoing cardiopulmonary bypass who were 6 months of age or less or underwent a repeat sternotomy.

AB - Background: The use of aprotinin in children undergoing cardiopulmonary bypass is controversial. We hypothesized that aprotinin would reduce blood product use and operative closure time in selected pediatric patients. Methods: For a 6-month period starting in October 1999, consecutive cardiopulmonary bypass patients 6 months of age or less (n = 18) or having a repeat sternotomy (n = 18) received aprotinin. Similar consecutive patients from the preceding 6 months served as controls (n = 35 and 41, respectively). Data extracted from medical records included preoperative clinical characteristics, operative and postoperative procedures, and total blood product use. Results: Patients in the aprotinin and control groups were well matched with regard to preoperative and intraoperative variables. Patients 6 months of age or less who received aprotinin required less operative closure time when compared with controls (median, 93 vs 127 minutes, p = 0.004), and trended toward requiring fewer red blood cell unit exposures (median, three vs five exposures, p = 0.07). Patients undergoing repeat sternotomy who received aprotinin required less operative closure time when compared with controls (mean, 126 vs 159 minutes, p = 0.007), fewer red blood cell unit exposures (median three vs four exposures, p = 0.002), and fewer fresh-frozen plasma unit exposures (median, zero vs one exposure, p = 0.007). Conclusions: Aprotinin reduced operative closure time and blood product exposure in pediatric patients undergoing cardiopulmonary bypass who were 6 months of age or less or underwent a repeat sternotomy.

UR - http://www.scopus.com/inward/record.url?scp=0037385540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037385540&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(02)04667-2

DO - 10.1016/S0003-4975(02)04667-2

M3 - Article

VL - 75

SP - 1261

EP - 1266

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -